Focus:
Uncategorised
-
5 June 2020
GlobalData Epidemiologist Update: Covid-19 cases continue to rise – mass gatherings a cause for concern
5 June Globally, the total confirmed cases of Covid-19 have reached over 6,658,000 with over 391,000 deaths and 2,886,000 recoveries. Globally, cases continue to rise with 4 June seeing one...
-
4 June 2020
The hydroxychloroquine debate continues
Hydroxychloroquine is an immunosuppressive drug approved for the treatment of malaria and repeatedly praised by US President Donald Trump, who claims to have taken it to ward off Covid-19. The...
-
28 May 2020
Clinical trials disrupted due to Covid-19 slowly resume
Many companies have announced that they are experiencing disruptions to their clinical trials for non-Covid-19 indications due to the strict lockdown measures that many countries have implemented. Many have delayed...
-
29 April 2020
GlobalData Epidemiologist Report: Covid-19 cases in Brazil exceed 66,000 – US, Spain and Italy have most reported cases
29 April Globally, there have been 3,061,521 cases of Covid-19 reported. The US, Spain and Italy are the three countries with the most reported cases. Brazil has the largest number...
-
28 April 2020
Economic outlook: GDP growth forecasts for EU and India worsen – UNIRO says Covid-19 will leave a legacy for years to come
28 April Morgan Stanley has revised down its GDP growth forecast for the European Union and is now predicting an 11.8% contraction in 2020. The US investment bank said: "In...
-
16 April 2020
Men, the elderly and people with pre-existing conditions most likely to die due to coronavirus, official data confirms
COVID-19 was the third most common cause of death in England and Wales last month, new Office Of National Statistics (ONS) data reveals. Almost one in ten deaths in March...
-
16 April 2020
Coronavirus company news summary
16 April 2020 Japan’s Fujifilm has expanded manufacturing capacity to boost production of its influenza drug Avigan that is being assessed to potentially treat Covid-19. Fujifilm estimates to increase the...
-
15 April 2020
Aligos to leverage Luxna’s tech to create anti-viral drugs
Aligos Therapeutics has broadened its license agreement with Osaka University's Luxna Biotech to develop anti-viral drugs against the virus causing Covid-19, as well as other respiratory viruses. According to the...